Business
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
- Data presented at Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society - - After up to 36 months of follow-up, extremity arterial trauma patients had high rates of limb salvage, low rates of infection, and no unprovoked structural failures - - Long-term durability results showed no dilatation nor narrowing of Symvess diameter out to 36 months - DURHAM, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company
About this update from Humacyte, Inc.
[{"type":"image","alt":"Humacyte, Inc","displaySize":"","headline":null,"caption":"Humacyte, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":57,"url":"https://media.zenfs.com/en/globenewswire.com/6664e34870555953d37f7abc79cd102e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/trBSY4KWXHpBRzQ_5qCqbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6664e34870555953d37f7abc79cd102e","width":300,"height":57}},"lazy":false},{"type":"text","content":"- Data presented at Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society - ","length":100,"tagName":"p"},{"type":"text","content":"- After up to 36 months of follow-up, extremity arterial trauma patients had high rates of limb salvage, low rates of infection, and no unprovoked structural failures - ","length":168,"tagName":"p"},{"type":"text","content":"- Long-term durability results showed no dilatation nor narrowing of Symvess diameter out to 36 months -","length":104,"tagName":"p"},{"type":"text","content":"DURHAM, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the presentation of long-term data assessing the durability of Symvess in extremity arterial trauma patients at the Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society (VESS) in Olympic Valley, CA.","length":454,"tagName":"p"},{"type":"text","content":"The presentation, titled “Long-Term Outcomes of the Acellular Tissue Engineered Vessel in Extremity Arterial Trauma Repair: Results from the V005 Trial,” was delivered by Michael Curi, MD, MPA, Chief, Division of Vascular Surgery, Vice Chair, Department of Surgery, Assoc Prof of Surgery, Rutgers – New Jersey Medical School. In the V005 trial, Symvess maintained long-term structural integrity, exhibited low infection rates, and supported high rates of limb salvage in patients who were followed for up to 36 months.","length":518,"tagName":"p"},{"type":"text","content":""These long-term results demonstrate the potential of Symvess to meet the needs of trauma patients when autologous vein is not available or feasible," said Dr. Curi. "During the V005 study, there were sustain...